ERBB2 and neoplasm: Other authors describe that the number of AgNORs correlates with tumour-free survival [28] or that the AgNOR analysis represents an additional tool for identifying, in the case of a limit-value HER2 status, further patients that can be considered for a trastuzumab therapy [29].